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sult from small vessel disease. Small vessel disease leads to lacunar infarcts and white matter lesions in the brain. The underlying mechanism is poorly controlled hypertension and/or diabetes mellitus, or a genetic component. In recent years, evidence accumulated that vascular risk factors and vascular diseases play an important role in the incidence and progression of mild cognitive impairment to manifest Alzheimer's disease.
The Whitehall II cohort is a prospective registry with a long observation period of almost 30 years. In this issue of the European Heart Journal, 2 the study group investigated the association between different levels of blood pressure and the later incidence of dementia. The results showed that blood pressure > _130 mmHg at age 50 is associated with an increased risk of dementia. This is no longer the case at ages of 60 and 70 years. This result may have consequences for the ongoing battle to define the blood pressure threshold which constitutes 'hypertension'. The authors clearly state that they study an association which does not necessarily mean that the relationship between higher levels of blood pressure and dementia is causal. The paper, however, contains information that is by far more important than the reported observations for blood pressure. Their table 1 (Abell et al.) shows biological variables, lifestyle factors, vascular risk factors, and socio-economic variable at age 50 which are associated with dementia at the end of follow-up. With the exception of diabetes mellitus and the intake of anti-hypertensive medication, all of these factors are associated with a higher risk of dementia. One could argue that in the context of the Whitehall II study dementia is not differentiated between vascular and degenerative dementia. This is not relevant, since vascular risk and lifestyle factors are associated with both forms of dementia. 3 In the last 20 years, a large number of small molecules and monoclonal antibodies have been developed to slow the conversion of mild cognitive impairment to dementia and the progression of dementia. The outcomes of these trials were a total disaster. 4 All phase III trials have been negative. As a consequence, many large pharmaceutical companies left the field of dementia research. Why have all attempts to prevent the progression of Alzheimer's disease failed so far? The availability of modern imaging techniques, e.g. amyloid positron emission tomography (PET), and biomarkers indicate that the disease process in Alzheimer's disease most probably starts 20-30 years before the first symptoms of cognitive impairment. 5 This indicates that any therapy which is implemented when symptoms occur is most probably too late. What is the relationship between these scientific results and the Whitehall II study? In the absence of effective medical therapy of dementia, major attempts have to be undertaken to identify vascular risk factors and lifestyle factors at age 40-50 on a population level. In Take home figure of the study of Livingston et al., the relative risk of different factors across the life span for dementia is shown. 5 Whether treatment of risk factors and modification of lifestyle factors would prevent dementia needs to be demonstrated. Randomized studies, however, would need to run for 5-10 years to show efficacy. As a consequence, we need a shift in our health policies. Instead of spending billions of Euros for the development of drugs against dementia, healthcare systems across the world should aim at identifying risk factors such as hypertension, obesity, smoking, poor diet, a low level of physical activity, and heavy alcohol consumption at ages 40-50, and treat those as aggressively as possible. Another way to prevent dementia is to invest in our schools and universities. High educational qualification protects from dementia. Editorial
